Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Increased sensitivity of test that detects the second deadliest cancer will save hundreds of lives, oncologists say ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

Please provide your email address to receive an email when new articles are posted on . In a prospective study, researchers enrolled 457 asymptomatic participants (mean age 61.4 years; 75% women) from ...

Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Multitarget stool DNA tests — which are becoming more popular in the United States — have shown increased sensitivity over fecal immunochemical tests (FITs) for early colorectal cancer (CRC) screening ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...